Yifei Sanjie Pills alleviates cancer-related skeletal muscle atrophy in mice possibly by lowering inflammatory insulin resistance
OBJECTIVE: To evaluate the effects of Yifei Sanjie Pills (YFSJ) on weight, strength, pathology, glycogen and lipid contents and metabolism of skeletal muscles in tumor-bearing mice and explore the therapeutic mechanism of YFSJ for cancer-related skeletal muscle atrophy.
METHODS: Sixteen female ICR mice bearing intraperitoneal Lewis lung adenocarcinoma xenografts were randomized into model group and YFSJ treatment group (daily dose of 4 g/kg for 21 days, n=8), with another 8 normal mice as the normal control group. The changes in body weight and gastrocnemius muscle weight of the mice were recorded. Liquid chromatography-mass spectrometry (LC-MS) was used to analyze the drug components in YFSJ entering the blood. Enzyme-linked immunosorbent assay was used to detect serum blood glucose and insulin concentrations and inflammatory cytokine levels in the serum and gastrocnemius. RNA-seq was performed to analyze the signaling pathways involved in the pathologies of the gastrocnemius muscle, and lipid contents in the muscle were observed using Oil red O staining. Adenosine triphosphatase staining was used to assess the metabolic intensity of the gastrocnemius muscle, and inflammatory cell infiltration and P-AKT level were evaluated using immunohistochemical staining; the contents of creatine kinase, lactate dehydrogenase and myoglobin in the gastrocnemius muscle were also detected.
RESULTS: Treatment with YFSJ significantly increased skeletal muscle strength and gastrocnemius muscle weight (P < 0.001) and reduced the levels of gastrocnemius muscle injury markers in the tumor-bearing mice (P < 0.01). RNA-seq and LC-MS showed that YFSJ alleviated gastrocnemius muscle injury in the tumor-bearing mice possibly by improving inflammatory infiltration, insulin resistance and lipid metabolism (P < 0.05). YFSJ lowered inflammatory cytokine levels in both the serum and gastrocnemius muscle (P < 0.05), reduced pro-inflammatory cell infiltration, increased P-AKT level, and improved glycogen and lipid contents and metabolic levels in the gastrocnemius muscle.
CONCLUSION: YFSJ alleviates cancer-related skeletal muscle atrophy possibly by reducing inflammatory insulin resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Nan fang yi ke da xue xue bao = Journal of Southern Medical University - 43(2023), 11 vom: 20. Nov., Seite 1839-1849 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Wu, Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer-related skeletal muscle atrophy |
|---|
| Anmerkungen: |
Date Revised 11.12.2023 published: Print Citation Status In-Process |
|---|
| doi: |
10.12122/j.issn.1673-4254.2023.11.02 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365723665 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365723665 | ||
| 003 | DE-627 | ||
| 005 | 20231229123510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.12122/j.issn.1673-4254.2023.11.02 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1227.xml |
| 035 | |a (DE-627)NLM365723665 | ||
| 035 | |a (NLM)38081600 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Wu, Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Yifei Sanjie Pills alleviates cancer-related skeletal muscle atrophy in mice possibly by lowering inflammatory insulin resistance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status In-Process | ||
| 520 | |a OBJECTIVE: To evaluate the effects of Yifei Sanjie Pills (YFSJ) on weight, strength, pathology, glycogen and lipid contents and metabolism of skeletal muscles in tumor-bearing mice and explore the therapeutic mechanism of YFSJ for cancer-related skeletal muscle atrophy | ||
| 520 | |a METHODS: Sixteen female ICR mice bearing intraperitoneal Lewis lung adenocarcinoma xenografts were randomized into model group and YFSJ treatment group (daily dose of 4 g/kg for 21 days, n=8), with another 8 normal mice as the normal control group. The changes in body weight and gastrocnemius muscle weight of the mice were recorded. Liquid chromatography-mass spectrometry (LC-MS) was used to analyze the drug components in YFSJ entering the blood. Enzyme-linked immunosorbent assay was used to detect serum blood glucose and insulin concentrations and inflammatory cytokine levels in the serum and gastrocnemius. RNA-seq was performed to analyze the signaling pathways involved in the pathologies of the gastrocnemius muscle, and lipid contents in the muscle were observed using Oil red O staining. Adenosine triphosphatase staining was used to assess the metabolic intensity of the gastrocnemius muscle, and inflammatory cell infiltration and P-AKT level were evaluated using immunohistochemical staining; the contents of creatine kinase, lactate dehydrogenase and myoglobin in the gastrocnemius muscle were also detected | ||
| 520 | |a RESULTS: Treatment with YFSJ significantly increased skeletal muscle strength and gastrocnemius muscle weight (P < 0.001) and reduced the levels of gastrocnemius muscle injury markers in the tumor-bearing mice (P < 0.01). RNA-seq and LC-MS showed that YFSJ alleviated gastrocnemius muscle injury in the tumor-bearing mice possibly by improving inflammatory infiltration, insulin resistance and lipid metabolism (P < 0.05). YFSJ lowered inflammatory cytokine levels in both the serum and gastrocnemius muscle (P < 0.05), reduced pro-inflammatory cell infiltration, increased P-AKT level, and improved glycogen and lipid contents and metabolic levels in the gastrocnemius muscle | ||
| 520 | |a CONCLUSION: YFSJ alleviates cancer-related skeletal muscle atrophy possibly by reducing inflammatory insulin resistance | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Yifei Sanjie Pills | |
| 650 | 4 | |a cancer-related skeletal muscle atrophy | |
| 650 | 4 | |a inflammatory insulin resistance | |
| 700 | 1 | |a Zuo, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, W |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, H |e verfasserin |4 aut | |
| 700 | 1 | |a Pi, D |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, L |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, L |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nan fang yi ke da xue xue bao = Journal of Southern Medical University |d 2006 |g 43(2023), 11 vom: 20. Nov., Seite 1839-1849 |w (DE-627)NLM16087646X |x 1673-4254 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:11 |g day:20 |g month:11 |g pages:1839-1849 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12122/j.issn.1673-4254.2023.11.02 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 11 |b 20 |c 11 |h 1839-1849 | ||